Nile tilapia (Oreochromis niloticus) is one of the most important aquaculture species farmed worldwide. However, the recent emergence of tilapia lake virus (TiLV) disease, also known as syncytial hepatitis of tilapia, has threatened the global tilapia industry. To gain more insight regarding the host response against the disease, the transcriptional profiles of liver in experimentally-infected and control tilapia were compared.
A 7-month experiment was carried out to determine the effects of different levels of probiotics (baker's yeast (Saccharomyces cerevisiae) and Bacillus subtilis) on Nile tilapia (Oreochromis niloticus) reared in low input ponds.
Nile tilapia (Oreochromis niloticus) is a globally significant aquaculture species rapidly gaining status as a farmed commodity. In West Africa, wild Nile tilapia genetic resources are abundant yet knowledge of fine-scale population structure and patterns of natural genetic variation are limited.
WorldFish initiated a selective breeding program in Abbassa--Egypt to develop and produce the genetically improved Nile tilapia strain known as “Genetically Improved Abbassa Nile tilapia (GIANT)”, adopting the same technology used for the Genetically Improved Farmed Tilapia (GIFT), in Asia. WorldFish provided the Ninth Generation (G9) broodstock of the GIANT to 11 Broodstock Multiplication Centers (BMC’s) in five governorates; these centres then disseminated improved mixed-sex fry to 160 tilapia hatcheries which supplied all-male fry to 1,500 fish farms in 2017.